VALE, LXRX & SVXY ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action
Back to Newsroom
Mentioned in this Article

VALE, LXRX & SVXY ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action

Tuesday, February 26, 2019 10:28 AM
Share this article now
Topic:
Advertorial

NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vale S.A. (NYSE: VALE)

Class Period: April 13, 2018 - January 28, 2019
Lead Plaintiff Deadline: March 29, 2019
For more info: www.bgandg.com/vale

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Vale had failed to adequately assess the risk and damage potential of a dam breach at its Feijão iron ore mine; (2) Vale's programs to mitigate health and safety incidents were inadequate; (3) consequently, several people were killed and hundreds more were reported as missing after Vale's dam at its Feijão iron ore mine was breached; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Class Period: March 11, 2016 - January 17, 2019

Lead Plaintiff Deadline: April 1, 2019
For more info: www.bgandg.com/lxrx.

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the data from Lexicon's Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in treating type 1 diabetes were not as positive as Lexicon represented; (2) the health risks posed by Sotagliflozin were severe enough to threaten its FDA approval prospects; and (3) as a result, Lexicon's public statements were materially false and misleading at all relevant times.

ProShares Short VIX Short-Term Futures ETF (NYSE: SVXY)

Class Period: shares purchased (1) pursuant to the May 15, 2017 Registration Statement and/or (2) between May 15, 2017 - February 5, 2018
Lead Plaintiff Deadline: April 1, 2019
For more info: www.bgandg.com/svxy

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that adverse information regarding the risks of investing in the Fund. Specifically, the complaint alleges that the Registration Statement failed to disclose that the Fund was threatened with catastrophic losses as a result of the Fund's flawed design and the low-volatility environment and acute liquidity risks that existed during the Class Period. The complaint continues to allege that throughout the Class Period defendants made substantially similar false and misleading statements as those contained in the Registration Statement in numerous financial reports and draft prospectuses and registration statements filed with the SEC.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

SOURCE: Bronstein, Gewirtz & Grossman, LLC

Bronstein, Gewirtz and Grossman, LLC
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions